Specialised Therapeutics (ST) commercialises new therapies and technologies for patients in Australia, New Zealand and across South-East Asia. Our GI oncology portfolio includes ABRAXANE® (nanoparticle albumin-bound paclitaxel) for metastatic breast cancer and pancreatic cancer, QINLOCK® (ripretinib) for gastrointestinal stromal tumours and PEMAZYRE® (pemigatinib) for cholangiocarcinoma. The broader portfolio spans haematology, neurology, ophthalmology and supportive care.